MEGHAN BAKER, FNP-C
Family Nurse Practitioner · FREMONT, CA
Individual Active NPI 1144839531
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 253 | 116,566 | $8,751,870 | $3,150,743 | $2,500,811 |
| 2023 | 274 | 125,371 | $9,238,300 | $3,126,463 | $2,486,956 |
| 2022 | 2,064 | 9,146 | $944,153 | $337,583 | $279,430 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 16,200 | $22 | $17 |
| J2350 | Injection, ocrelizumab, 1 mg | 11,700 | $59 | $47 |
| J3262 | Injection, tocilizumab, 1 mg | 10,920 | $6 | $5 |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 8,610 | $18 | $14 |
| J1306 | Injection, inclisiran, 1 mg | 5,964 | $12 | $9 |
| J2182 | Injection, mepolizumab, 1 mg | 2,900 | $30 | $24 |
| J2357 | Injection, omalizumab, 5 mg | 2,745 | $38 | $30 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 2,160 | $31 | $25 |
| J0517 | Injection, benralizumab, 1 mg | 1,110 | $160 | $127 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 979 | $0 | $0 |
| 96372 | Injection of drug or substance under skin or into muscle | 271 | $15 | $12 |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | 219 | $148 | $118 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Family Nurse Practitioner | 363LF0000X | ✓ | 95013697 | CA |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Family Nurse Practitioner providers in California
- NPI 1154962199
- NPI 1942734744
- NPI 1700378460
- NPI 1093219321
- NPI 1851469373
- NPI 1225327745
- NPI 1225764640
- NPI 1104615806
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.